Stemetil Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

stemetil

sanofi-aventis australia pty ltd - prochlorperazine maleate; prochlorperazine mesylate -

Antinaus Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

antinaus

viatris limited - prochlorperazine maleate 5mg; prochlorperazine maleate 5mg - tablet - 5 mg - active: prochlorperazine maleate 5mg excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose povidone active: prochlorperazine maleate 5mg excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose povidone - antinaus is used in vertigo due to meniere's syndrome, labyrinthitis and other causes, and for nausea and vomiting from whatever cause. it may also be used for migraine, schizophrenia (particularly in the chronic stage), acute mania and as an adjunct to the short term management of anxiety.

Antinaus Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

antinaus

viatris limited - prochlorperazine maleate 5mg; prochlorperazine maleate 5mg - tablet - 5 mg - active: prochlorperazine maleate 5mg excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose povidone active: prochlorperazine maleate 5mg excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose povidone - for the treatement of nausea associated with migrane.

Solian Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

solian

sanofi-aventis new zealand limited - amisulpride 100 mg/ml;   - oral solution - 100 mg/ml - active: amisulpride 100 mg/ml   excipient: caramel hydrochloric acid methyl hydroxybenzoate potassium sorbate propyl hydroxybenzoate purified water sweetener gesweet 01002023 - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.